Bottom line
PHSTX vs SWHFX: the short answer
PHSTX (Putnam Global Health Care Fund) and SWHFX (Schwab Health Care Fund) are both mutual funds.
SWHFX is cheaper at 0.8% vs 1.04% — a difference of $24 a year per $10,000 invested.
Over five years, PHSTX returned +6.5% a year vs +6.5% for SWHFX (reporting dates differ).
PHSTX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
PHSTX vs SWHFX side by side
| PHSTX | SWHFX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Franklin Templeton | Schwab |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.04% | 0.8% |
| Annual cost per $10k | $104 | $80 |
| 10-yr cost on $10k (prospectus) | $1,772 | $990 |
| Max front load | 5.75% | — |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | −4.6% | +15.9% |
| 5-yr return (annualized) | +6.5% | +6.5% |
| 10-yr return (annualized) | +6.9% | +8.1% |
| Best quarter | +17.5% | +15.3% |
| Worst quarter | −12.3% | −12.1% |
| Net assets (fund) | $1.5B | $642.3M |
| Number of holdings | 115 | 80 |
| Portfolio turnover | 67% | 41% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PHSTX | SWHFX | Difference |
|---|---|---|---|
| 2024 | +1.3% | +0.1% | +1.2% |
| 2023 | +9.0% | +0.7% | +8.4% |
| 2022 | −4.7% | −4.7% | −0.0% |
| 2021 | +19.4% | +23.3% | −3.9% |
| 2020 | +15.9% | +12.9% | +3.1% |
| 2019 | +30.2% | +17.6% | +12.6% |
| 2018 | −0.6% | +4.0% | −4.6% |
| 2017 | +15.3% | +20.2% | −4.9% |
| 2016 | −11.7% | −4.4% | −7.3% |
Source: Fund prospectus bar charts
Holdings overlap
14 of PHSTX's top 25 holdings also appear in SWHFX's top 25.
| Holding | PHSTX | SWHFX |
|---|---|---|
| Eli Lilly & Co. | 13.15% | 13.92% |
| Johnson & Johnson | 8.46% | 6.94% |
| UnitedHealth Group, Inc. | 6.93% | 4.74% |
| AbbVie, Inc. | 6.05% | 5.81% |
| Novartis AG | 5.13% | 2.92% |
| Merck & Co., Inc. | 4.88% | 4.98% |
| Thermo Fisher Scientific, Inc. | 4.50% | 2.16% |
| Sanofi SA | 3.23% | 1.31% |
| Roche Holding AG | 2.79% | 2.29% |
| Gilead Sciences, Inc. | 2.63% | 3.24% |
| Vertex Pharmaceuticals, Inc. | 1.97% | 1.89% |
| Boston Scientific Corp. | 1.80% | 1.60% |
| Bristol-Myers Squibb Co. | 1.75% | 2.44% |
| Amgen, Inc. | 1.11% | 2.58% |
Source: SEC Form N-PORT
PHSTX top 10
- Eli Lilly & Co. — 13.15%
- Johnson & Johnson — 8.46%
- UnitedHealth Group, Inc. — 6.93%
- AbbVie, Inc. — 6.05%
- Novartis AG — 5.13%
- Merck & Co., Inc. — 4.88%
- AstraZeneca plc — 4.67%
- Thermo Fisher Scientific, Inc. — 4.50%
- Intuitive Surgical, Inc. — 4.04%
- Sanofi SA — 3.23%
SWHFX top 10
- Eli Lilly & Co — 13.92%
- Johnson & Johnson — 6.94%
- AbbVie Inc — 5.81%
- Merck & Co Inc — 4.98%
- UnitedHealth Group Inc — 4.74%
- Gilead Sciences Inc — 3.24%
- Novartis AG — 2.92%
- Amgen Inc — 2.58%
- Bristol-Myers Squibb Co — 2.44%
- Medtronic PLC — 2.29%
FAQ
What is the difference between PHSTX and SWHFX?
Which is cheaper, PHSTX or SWHFX?
Should I own both PHSTX and SWHFX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.